NewsRoom Articles - Page 63 of 154 - PsychedelicNewsWire (PNW)

FridayApr 08, 2022 3:12 pm

Oregon Health Authority Admits Proposed Psilocybin Rules May Negatively Impact Lower-Income Individuals

Recently, the Oregon Health Authority announced its latest revision of proposed rules at the start of this month. The rules were released ahead of the state’s psilocybin services program, which is scheduled to open to the private and public business sector in early 2023. Regarding its proposal, the Oregon Health Authority stated that the rules would impact all psilocybin testing laboratories, psilocybin facilitators, psilocybin service centers, psilocybin manufacturers and psilocybin training programs in the state. These rules, which focus on the manufacture and testing of psilocybin products and training modules for aspiring licensed facilitators, may have a negative effect on…

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

ThursdayApr 07, 2022 3:01 pm

UNC Professor Reveals Personal Motive in Studying Psychedelics for Mental Health

Professor Bryan Roth of the University of North Carolina at Chapel Hill says that psychedelic drugs had demonstrated in studies that they had miraculous effects on mental illnesses. Roth also revealed that his research was personal, explaining that his mother suffered from schizophrenia all her life, having had her first episode when he was about five. This, Roth said, has motivated him to learn more about what goes on in the brain. Schizophrenia is a severe mental disorder in which individuals interpret reality in an abnormal way. Patients suffer from delusions, hallucinations and disordered behavior and thinking. After being legally…

WednesdayApr 06, 2022 3:09 pm

How You Can Participate in a Psychedelic Clinical Trial

These last few years, clinical trials on the use of psychedelics such as MDMA, LSD or psilocybin as treatments for various mental health conditions have increased significantly. For clinical trials to run, however, participants are needed. At first glance, it may seem easy to enroll individuals for trials given that quite a number of people suffer from mental conditions such as depression and anxiety. However, for an individual to be enrolled into a clinical trial, they must meet the stipulated inclusion criteria in order to be eligible. Below are steps on how one can enroll in a psychedelic clinical trial.…

TuesdayApr 05, 2022 3:29 pm

Ibogaine Blocks Reward Pathways in Alcohol-Dependent Mice

New research has found that ibogaine blocks some of the abuse-related effects of alcohol in mice. Ibogaine is a natural product extracted from the Tabernanthe iboga plant. It is commonly used during religious ceremonies in the form of tea and is extracted from the plant’s root, bark and stem. Alcohol use disorder is a chronic illness that is characterized by uncontrollable drinking. Symptoms include the repeated consumption of alcohol despite related health and legal problems. This disorder is a leading cause of death and absenteeism globally and is recognized as a global public health issue. However, the current treatments used…

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

TuesdayApr 05, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”)…

MondayApr 04, 2022 1:46 pm

Activists in Michigan Start Signature Collection Efforts for Psychedelic Legalization Ballot Measure

Earlier this week, activists in the state of Michigan began a signature drive to collect signatures to place an initiative to legalize the sharing, possession and cultivation of psychedelics on the coming statewide ballot. Students for Sensible Drug Policy, a youth-led organization, and the Decriminalize Nature chapter in Michigan are collaborating in this effort. The measure would establish a system for the spiritual and therapeutic use of psychedelic substances. The legislation also permits counseling, spiritual, harm reduction, therapeutic, guidance, supervision and associated supportive services. The initiative also authorizes entities that have acquired a certificate of need from the state’s Department…

MondayApr 04, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year During a recent interview on The Jesse Tee Show, Stang noted the company intends to scale its ketamine clinics as well as build infrastructure to accommodate expanded psychedelic healing The company hopes to utilize its expanded infrastructure to help destigmatize mental health conditions Delic Holdings (CSE: DELC)…

FridayApr 01, 2022 3:03 pm

Psychedelics May Boost Connectedness with Nature

A new study has looked into how therapeutic psychedelic administration combined with the calm properties of nature-based settings has the capacity to improve an individual’s mental well-being as well as bolster their relationship with nature. The study was conducted by a team of researchers from the Center for Psychedelic Research at Imperial College in London. Its findings were reported in “Health Psychology.” Contact with nature and the therapeutic administration of psychedelics has been linked to similar psychological mechanisms, including amplified states of transcendent experiences and awe, increased psychological connectedness and reduced rumination, which are all processes associated with improvements in…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000